These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 8943175)
1. Diagnostic dilemma of small incidentally discovered adrenal masses: role for 131I-6beta-iodomethyl-norcholesterol scintigraphy. Kloos RT; Gross MD; Shapiro B; Francis IR; Korobkin M; Thompson NW World J Surg; 1997 Jan; 21(1):36-40. PubMed ID: 8943175 [TBL] [Abstract][Full Text] [Related]
2. The role of adrenocortical scintigraphy in the evaluation of unilateral incidentally discovered adrenal and juxtaadrenal masses. Nakajo M; Nakabeppu Y; Yonekura R; Iwashita S; Goto T Ann Nucl Med; 1993 Aug; 7(3):157-66. PubMed ID: 8217490 [TBL] [Abstract][Full Text] [Related]
3. Distinguishing benign from malignant euadrenal masses. Gross MD; Shapiro B; Bouffard JA; Glazer GM; Francis IR; Wilton GP; Khafagi F; Sonda LP Ann Intern Med; 1988 Oct; 109(8):613-8. PubMed ID: 3421574 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of the large adrenal mass. Khafagi FA; Gross MD; Shapiro B; Glazer GM; Francis I; Thompson NW Br J Surg; 1991 Jul; 78(7):828-33. PubMed ID: 1873713 [TBL] [Abstract][Full Text] [Related]
6. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. Maurea S; Klain M; Mainolfi C; Ziviello M; Salvatore M J Nucl Med; 2001 Jun; 42(6):884-92. PubMed ID: 11390552 [TBL] [Abstract][Full Text] [Related]
7. The value of 18F-FDG PET-CT and 131I-norcholesterol scintigraphy in the characterization of high-risk adrenal masses. Riaz S; Syed R; Aziz TA; Alnaim A; Chung TT; Wan S; Kurzawinski TR; Bomanji J Nucl Med Commun; 2020 Mar; 41(3):189-195. PubMed ID: 31895761 [TBL] [Abstract][Full Text] [Related]
8. High risk of malignancy in patients with incidentally discovered adrenal masses: accuracy of adrenal imaging and image-guided fine-needle aspiration cytology. Lumachi F; Borsato S; Tregnaghi A; Marino F; Fassina A; Zucchetta P; Marzola MC; Cecchin D; Bui F; Iacobone M; Favia G Tumori; 2007; 93(3):269-74. PubMed ID: 17679462 [TBL] [Abstract][Full Text] [Related]
9. [Role of adrenocortical scintigraphy in the exploration of incidentally discovered tumors]. Delemer B; Gibold C; Caron J; Liehn JC; Delisle MJ Ann Endocrinol (Paris); 1992; 53(4):147-52. PubMed ID: 1339063 [TBL] [Abstract][Full Text] [Related]
10. Quantitative evaluation of norcholesterol scintigraphy, CT attenuation value, and chemical-shift MR imaging for characterizing adrenal adenomas. Yoh T; Hosono M; Komeya Y; Im SW; Ashikaga R; Shimono T; Tsuchiya N; Okada M; Hanada K; Yagyu Y; Nishimura Y; Murakami T Ann Nucl Med; 2008 Jul; 22(6):513-9. PubMed ID: 18670858 [TBL] [Abstract][Full Text] [Related]
11. Quantitative imaging characterization of hypersecreting or nonhypersecreting adrenal adenomas: comparison between iodine-131 norcholesterol uptake and magnetic resonance signal intensity ratios. Maurea S; Imbriaco M; Mollica C; Pace L; Salvatore M Nucl Med Commun; 2011 Jun; 32(6):535-41. PubMed ID: 21448089 [TBL] [Abstract][Full Text] [Related]
12. A case of ganglioneuroma in which 131I-6beta-iodomethyl-19-norcholest-5(10)-en-3beta-ol scintigraphy showed high uptake in the adrenal gland leading to a misdiagnosis. Fukumitsu N; Ashida H; Ogi S; Uchiyama M; Mori Y; Ikemoto I; Sakamoto N; Tojo K; Kawakami M Ann Nucl Med; 2006 Jan; 20(1):69-73. PubMed ID: 16485578 [TBL] [Abstract][Full Text] [Related]
13. [Contribution of the scintigraphy with iodocholesterol (I-COL) to the diagnosis and characterization of silent adrenal masses]. Rodado Marina S; Aguirre Sánchez-Covisa M; García Vicente AM; Poblete García VM; Ruiz Solís S; Cortés Romera M; Soriano Castrejón A Rev Esp Med Nucl; 2004; 23(3):166-73. PubMed ID: 15153359 [TBL] [Abstract][Full Text] [Related]
14. 131I-6β-iodomethyl-19-norcholesterol adrenal scintigraphy as an alternative to adrenal venous sampling in differentiating aldosterone-producing adenoma from bilateral idiopathic hyperaldosteronism. Saiga A; Yokota H; Nagano H; Sawada K; Kubota Y; Wada T; Horikoshi T; Tanaka T; Uno T Nucl Med Commun; 2020 Dec; 41(12):1226-1233. PubMed ID: 32956247 [TBL] [Abstract][Full Text] [Related]
15. SPECT semiquantitative analysis of adrenocortical (131)I-6 beta iodomethyl-norcholesterol uptake to discriminate subclinical and preclinical functioning adrenal incidentaloma. La Cava G; Imperiale A; Olianti C; Gheri GR; Ladu C; Mannelli M; Pupi A J Nucl Med; 2003 Jul; 44(7):1057-64. PubMed ID: 12843220 [TBL] [Abstract][Full Text] [Related]
16. Incidentally discovered adrenal masses. Kloos RT; Gross MD; Francis IR; Korobkin M; Shapiro B Endocr Rev; 1995 Aug; 16(4):460-84. PubMed ID: 8521790 [TBL] [Abstract][Full Text] [Related]
17. Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques. Maurea S; Caracò C; Klain M; Mainolfi C; Salvatore M Q J Nucl Med Mol Imaging; 2004 Sep; 48(3):188-97. PubMed ID: 15499292 [TBL] [Abstract][Full Text] [Related]
18. [The role of adrenal gland x-ray computed tomography and scintigraphy using radiolabelled norcholesterol in the etiological diagnosis of primary hyperaldosteronism]. Abram M; Peltier P; Murat A; Chupin M; Dupas B; Gaillard F; Chatal JF; Charbonnel B Rev Med Interne; 1993; 14(7):691-7. PubMed ID: 8191071 [TBL] [Abstract][Full Text] [Related]
19. Adrenocortical scintigraphy with 131I-6-beta-iodomethyl-norcholesterol (NP 59) in bilateral adrenocortical carcinoma. Ruíz Hernández G; Pallarés FJ; Bartual AR; Tenes Rodrigo S; Ampudia-Blasco FJ; de Avila y Avalos CR Nuklearmedizin; 1998 Jun; 37(4):141-5. PubMed ID: 9650214 [TBL] [Abstract][Full Text] [Related]
20. Case report: failure of adrenal scintigraphy to exhibit 131I cholesterol uptake in a CT-demonstrated, surgically proven aldosteronoma. Salam Z; Lubbos H; Martinez C; Mozley PD; Miller JL; Rose LI Am J Med Sci; 1996 Sep; 312(3):130-2. PubMed ID: 8783680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]